Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis.

ABSTRACT:

Objectives

This meta-analysis investigated the use of fluvoxamine for the treatment of nonhospitalized patients with COVID-19.

Methods

PubMed, Web of Science, Ovid medline, Embase, Scopus, Cochrane Library databases, and ClinicalTrials.gov were searched for studies published before June 25, 2022. Only clinical studies that compared the efficacy and safety of fluvoxamine with other alternatives or placebos in the treatment of nonhospitalized patients with COVID-19 were included.

Results

Four studies with 1814 patients, of whom 912 received fluvoxamine, were included in this study. Compared with the control group receiving placebo or no therapy, the study group receiving fluvoxamine demonstrated a lower risk of hospitalization and emergency department (ED) visits (odds

SUBMITTER: Lu LC 

PROVIDER: S-EPMC9556767 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature